Research programme: anticancer protease inhibitors - Curacyte

Drug Profile

Research programme: anticancer protease inhibitors - Curacyte

Alternative Names: CJ-463 uPA inhibitor; CJ-730 matriptase inhibitor; Matriptase inhibitors - Curacyte; Urokinase plasminogen activator inhibitors - Curacyte

Latest Information Update: 03 Aug 2007

Price : $50

At a glance

  • Originator Curacyte AG
  • Class Small molecules
  • Mechanism of Action Hepatocyte growth factor inhibitors; Matriptase inhibitors; Peptide hydrolase inhibitors; Urokinase-type plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 18 Oct 2005 Preclinical trials in Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top